<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Wechsler, Lawrence</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">No Advantage for Percutaneous Closure of PFO versus Medical Therapy in Reducing Recurrent Neurological Events</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">The CLOSURE I trial [NCT00201461] was conducted to determine if percutaneous patent foramen ovale closure using the STARFlex® Septal Closure System in combination with medical therapy, is superior to medical therapy alone to prevent recurrent ischemic neurological symptoms in patients with transient ischemic attack or ischemic stroke.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>